Podcasts about bialy

▶️Episode 222 ➗Guest : @tahabialy is a concept Artist from Cairo, Egypt. ✳️For full version of the podcast you can visit any podcast platform and search "kouryer podcast". For contact: Instagram: @tahabialy Artstation: https://www.artstation.com/taha_elbialy1995 00:00 - Start 00:40 - give a little introduction on how you got into visual arts and design?                                 05:00 - what is your main branch of design that you're focusing on? and tell us about your experience from the start till now on it?                                      08:20 - how does your design process usually go anytime you want to start working on a design project?   12:40 - what was the first art job paycheck you ever got what was it for and how did you feel at the time? 15:00 - have you ever used your dreams as inspirtaion for your works?  15:50 - who are your favorite artists and designers? (that have inspired you the most)   17:20 - what are you working on right now that you can tell us? What project is it?     18:30 - general art chat mental health               25:00 - what area beside that you're working on your interest to explore and learn? 27:00 - Time capsule #TahaElBialy #conceptart #ramtindeghat #kouryer #kouryerpodcast #podcast #digitalart #artpodcast #blender .................... Font used in the podcast's graphics by : https://www.instagram.com/jeremynelson42/?hl=en The V1 release of Yeager displayed above is Free for Personal + Commercial Use. Sole ownership and rights to the typeface belong to Jeremy Nelson + Jeremy Nelson Design. Distribution of the typeface is permissible upon request. For further questions and inquiries please contact me directly: jeremynelsondesign.com https://www.jeremynelsondesign.com/case-studies/yeager .................... Intro/outro music by: https://www.youtube.com/@audiolibrary_ Tell Me – LiQWYD (No Copyright Music) - https://youtu.be/telMC7ADrDA

▶️Episode 223 ➗Guest : @memo_bialy is a Character designer and layout artist from Cairo, Egypt. ✳️For full version of the podcast you can visit any podcast platform and search "kouryer podcast". For contact: Instagram: @memo_bialy Artstation: https://mohamedmemo.artstation.com/ 00:00 - Start 01:45 - give a little introduction on how you got into visual arts and design?                                            04:50 - what is your main branch of design that you're focusing on? and tell us about your experience from the start till now on it?                                      10:40 - how does your design process usually go anytime you want to start working on a design project?   13:20 - have you ever used your dreams as inspirtaion for your works?  15:55 - who are your favorite artists and designers? (that have inspired you the most)   17:20 - any advice and tips for a good portfolio and resume for artists? 20:00 - general art chat 22:30 - what are you working on right now that you can tell us? What project is it?                    25:30 - what area beside that you're working on your interest to explore and learn? 28:00 - Time capsule #MohamedElbialy #conceptart #ramtindeghat #kouryer #kouryerpodcast #podcast #digitalart #artpodcast #blender .................... Font used in the podcast's graphics by : https://www.instagram.com/jeremynelson42/?hl=en The V1 release of Yeager displayed above is Free for Personal + Commercial Use. Sole ownership and rights to the typeface belong to Jeremy Nelson + Jeremy Nelson Design. Distribution of the typeface is permissible upon request. For further questions and inquiries please contact me directly: jeremynelsondesign.com https://www.jeremynelsondesign.com/case-studies/yeager .................... Intro/outro music by: https://www.youtube.com/@audiolibrary_ Tell Me – LiQWYD (No Copyright Music) - https://youtu.be/telMC7ADrDA

BRAD BIALY KNOWS HOW PARENTS FEEL As his son was a student at STEM High School when two shooters killed Kendrick Castillo. He and his wife want to do something to help other families who have gone through a dangerous stressful situation but he just doesn't know how. We figured maybe a conversation could get something started. He's on at 1.

It's a Super Bowl bound podcast where we can't help but get a little giddy, and our guest today had to seek out a sports bar in Costa Rica just to see the game! But, as you'll hear, it couldn't have turned out any better for her. Even though it's hard to focus on food right now with Eagles mania, somehow we managed to do it. It's called commitment, people! So, between food and Eagles talk, we dig deep into the genesis of one of the coolest Philadelphia stories you'll ever hear of destiny intervening in someone's life and putting them on a path of passion and purpose, and how Farmer Jawn's founder, Christa Barfield, found her love for farming after she burned out from her career and booked a trip to Martinique on a whim.  Besides this incredibly inspiring story, here's what else we talked about: The corner store dilemma and what it means to reconceptualize it The evolution of Her Place Supper Club Marisa's eye-opening experience at Roxanne's The incredible and groundbreaking Honeysuckle Provisions Delicious Haitian Pork Griot Eating offals and why they're so damn delicious A South Philly secret supper club A brand new gelato shop in Fishtown from a gelato connoisseur Why you need to go to Wilmington to eat: think smoked red cabbage Eli travels to New Jersey for his best bite at one of the best restaurants in our region Why you need to go to Southwark and order the duck A brand new vegan and gluten-free bakery in South Philly Why you need to run to Reading Terminal and eat Bialys Each of our go-to bagel orders An exciting dinner inside of a heated greenhouse that you are going to want to go to A Jalen Hurts surprise in a bottle Why you should have a thermometer at home when frying foods Marisa admits to never seasoning a very important part of cooking pasta A brand new hoagie shop in West Philadelphia Forsythia restaurant reopens after an indoor natural disaster An incredibly close win for the Delicious City supper club tickets And of course we could not do this without our amazing partners, who are as passionate about food and drink as we are: For the most tasty, healthy, and satisfying salads and noodle dishes in Philly, click here to order Honeygrow If your restaurant or company wants to be in the headlines for all the right reasons, click here to discover how Peter Breslow Consulting and PR can take your business to the next level Connect with us on Instagram and, of course, share your eating adventures with us as well as tag us in your posts so we can talk about them on air!  

He makes me lie down in green pastures. He leads me beside still waters. 他讓我安躺在草地上，領我到靜水旁。 本集節目有： ✅ Psalm 23 詩篇第23篇 ； ✅ How to Make Bialy 波蘭洋蔥麵包的做法； ✅ Home Economics 雙語家政課。

Today we celebrate out milestone 400th episode with a special tribute to one of the all time great TV dramas, which recently concluded it's brilliant run. Better Call Saul is the rare spinoff that not only lived up to its parent show, it actually surpassed it. Today I'm joined by writer/director/executive producer Thomas Schnauz, actors Patrick Fabian (Howard Hamlin) and Peter Diseth (Bill Oakley), casting director Sharon Bialy and journalist and cultural critic Carrie Wittmer, plus I revisit my 2020 conversation with Jimmy McGill himself, Bob Odenkirk. Thanks for everyone who joined us today, producer Georgia Mooney for helping pull this together and to everyone who has joined me for the past eight years and 400 episodes, either as guest or listener. We're just getting started!

In Chelm, sometimes a good deed comes with a twist. (A bialy is similar to a bagel; round, but instead of a hole all the way through, it has a depressed middle that is filled with onions or poppy seeds or both.) From "Tales of The Wise Fools of Chelm," available on Amazon.com in paperback and Kindle. https://amzn.to/3VpWj7y

If we want to effectively persuade, treat everyone with respect, irrespective of their roles.  Dave & Anne discuss why it's important to treat EVERYONE as if they are the most important person around. Dave Rosenberg: https://lockedonleadership.com Anne Bonney: https://yourchangespeaker.com

Kathy Burns and Sally Edmonds from the Pet Alliance of Greater Orlando join us once again, and bring along Bialy the beagle, one of 4,000 beagles rescued from a mass-breeding facility in Virginia riddled with animal welfare concerns. The Pet Alliance rescued 15 beagles, and although more than half have found their forever homes, there are others still looking for theirs. You can see all of the animals available for adoption at petallianceorlando.org or give them a call at (407) 351-7722.

Wer hat die besten Fans? Wir! Sandra war in Polen und hat uns einen Gin mitgebracht, den Bialy Boacin Gin. Wir sprechen über diesen und versuchen mit dem wenigen Wissen das wir über Polen haben zu punkten. Wir nähern uns langsam der Sommerpause, das merken wir und schauen das wir. Aber jetzt erstmal viel Spaß mit dieser. 

Special Guest Jimmy Graham joins the program. Graham is a retired Navy SEAL and CEO of Able Shepard, a security and safety training program that teaches students how to respond and utilize protective tactics in threatening environments. Guest Brad Bialy calls in. Bialy is the father of a Highlands Ranch STEM School shooting survivor.  See omnystudio.com/listener for privacy information.

Biały Prorok, który nawiedził obie Ameryki w pierwszym wieku naszej ery, z pewnością wiedział, jak zrobić wejście, którego ludzie nigdy nie zapomną. Według przekazywanych przez rdzennych mieszkańców Ameryki legend, gdy Bóg Sprawiedliwy po raz pierwszy pojawił się na wyspach Polinezji, towarzyszyły mu trzy statki z wielkimi żaglami, które przypominały ogromne ptaki z uniesionymi skrzydłami, świecące złotym blaskiem w świetle poranka. Ludzie obserwujący te wydarzenia byli skostniali i nie byli w stanie się poruszyć...

Adam Bialy is the founder and CEO of Fiat Republic, the compliance-first, API-driven and highly secure and scalable bridge between banks and crypto. In this episode, Adam and Pete Townsend talk through the Fiat Republic vision, the current state of play between banks and crypto platforms that make Fiat Republic such a strong proposition, Adam's unique leadership style, raising a $3.5mn seed round…and a little something about Taylor Swift! This episode of MoneyNeverSleeps is sponsored by Philip Lee, one of Ireland's fastest-growing corporate law firms and expert advisors at the heart of the Dublin and London start-up, fintech and crypto communities. LINKS: Episode title inspired by Mainstream by OutKast Learn more about Fiat Republic and connect with Adam Bialy Leave a review and subscribe on Podchaser| Apple Podcasts | Spotify| Google| Overcast Check out our MoneyNeverSleeps website Subscribe to our newsletter on Substack Follow MoneyNeverSleeps on Twitter Follow Eoin Fitzgerald on Twitter Follow Pete Townsend on Twitter Get in touch at info@moneyneversleeps.ie --- Support this podcast: https://anchor.fm/moneyneversleeps/support

In this mini episode Greg and Tery follow up the story of the lucky dog who found a new home thanks to Tery and fellow Field Nut, Rob Danielson. All because of being part of the awesome Field notes community. Rob's post on Facebook - "Thank you Tee Lock for driving 1000 miles to bring me my new friend. Baby's new life name will be…Bialy. I love food names for pets and wanted to honor my best friend Bagel who crossed the rainbow bridge 6 months ago. Another round bread product! In case you are unfamiliar with what a Bialy is, I've provided a link. Today is the first day of the rest of her life, free of violence and negativity. Note: full name is Onion Bialy with Chive Cream Cheese."

Sins Of Omission: The AZT Scandal By Celia Farber Spin Nov. 1989 On a cold January day in 1987, inside one of the brightly-lit meeting rooms of the monstrous FDA building, a panel of 11 top Aids doctors pondered a very difficult decision. They had been asked by the FDA to consider giving lightning-quick approval to a highly toxic drug about which there was very little information. Clinically called Zidovudine, but nicknamed AZT after its components, the drug was said to have shown a dramatic effect on the survival of Aids patients. The study that had brought the panel together had set the medical community abuzz. It was the first flicker of hope - people were dying much faster on the placebo than on the drug.  But there were tremendous concerns about the new drug. It had actually been developed a quarter of a century earlier as a cancer chemotherapy, but was shelved and forgotten because it was so toxic, very expensive to produce, and totally ineffective against cancer. Powerful, but unspecific, the drug was not selective in its cell destruction.  Drug companies around the world were sifting through hundreds of compounds in the race to find a cure, or at least a treatment, for Aids. Burroughs Wellcome, a subsidiary of Wellcome, a British drug company, emerged as the winner. By chance, they sent the failed cancer drug, then known as Compound S, to the National Cancer Institute along with many others to see if it could slay the Aids dragon, HIV. In the test tube at least, it did.  At the meeting, there was a lot of uncertainty and discomfort with AZT. The doctors who had been consulted knew that the study was flawed and that the long-range effects were completely unknown. But the public was almost literally baying at the door. Understandably, there was immense pressure on the FDA to approve AZT even more quickly than they had approved thalidomide in the mid-60s, which ended up causing drastic birth defects.  Everybody was worried about this one. To approve it, said Ellen Cooper, an FDA director, would represent a "significant and potentially dangerous departure from our normal toxicology requirements."  Just before approving the drug, one doctor on the panel, Calvin Kunin, summed up their dilemma. "On the one hand," he said, "to deny a drug which decreases mortality in a population such as this would be inappropriate. On the other hand, to use this drug widely, for areas where efficacy has not been demonstrated, with a potentially toxic agent, might be disastrous."  "We do not know what will happen a year from now," said panel chairman Dr. Itzhak Brook. "The data is just too premature, and the statistics are not really well done. The drug could actually be detrimental." A little later, he said he was also "struck by the facts that AZT does not stop deaths. Even those who were switched to AZT still kept dying."  "I agree with you," answered another panel member, "There are so many unknowns. Once a drug is approved there is no telling how it could be abused. There's no going back."  Burroughs Wellcome reassured the panel that they would provide detailed two-year follow-up data, and that they would not let the drug get out of its intended parameters: as a stopgap measure for very sick patients.  Dr. Brook was not won over by the promise. "If we approve it today, there will not be much data. There will be a promise of data," he predicted, "but then the production of data will be hampered." Brook's vote was the only one cast against approval.  'There was not enough data, not enough follow-up," Brook recalls. "Many of the questions we asked the company were answered by, 'We have not analyzed the data yet,' or 'We do not know.' I felt that there was some promising data, but I was very worried about the price being paid for it. The side effects were so very severe. It was chemotherapy. Patients were going to need blood transfusions. That's very serious.  "The committee was tending to agree with me," says Brook, "that we should wait a little bit, be more cautious. But once the FDA realized we were intending to reject it, they applied political pressure. At about 4 p.m., the head of the FDA's Center for Drugs and Biologics asked permission to speak, which is extremely unusual. Usually they leave us alone. But he said to us, 'Look, if you approve the drug, we can assure you that we will work together with Burroughs Wellcome and make sure the drug is given to the right people.' It was like saying 'please do it.'"  Brad Stone, FDA press officer, was at that meeting. He says he doesn't recall that particular speech, but that there is nothing 'unusual" about FDA officials making such speeches at advisory meetings. "The people in that meeting approved the drug because the data the company had produced proved it was prolonging life. Sure it was toxic, but they concluded that the benefits clearly outweighed the risks."  The meeting ended. AZT, which several members of the panel still felt uncomfortable with and feared could be a time bomb, was approved.  Flash forward: August 17, 1989. Newspapers across America banner-headlined that AZT had been "proven to be effective in HIV antibody-positive, asymptomatic and early ARC patients," even through one of the panel's main concerns was that the drug should only be used in a last-case scenario for critically-ill AIDS patients, due to the drug's extreme toxicity. Dr. Anthony Fauci, head of the National Institutes of Health (NIH), was now pushing to expand prescription.  The FDA's traditional concern had been thrown to the wind. Already the drug had spread to 60 countries and an estimated 20.000 people. Not only had no new evidence allayed the initial concerns of the panel, but the follow-up data, as Dr. Brook predicted, had fallen by the waysite. The beneficial effects of the drug had been proven to be temporary. The toxicity, however stayed the same.  The majority of those in the AIDS afflicted and medical communities held the drug up as the first breakthrough on AIDS. For better or worse, AZT had been approved faster than any drug in FDA history, and activists considered it a victory. The price paid for the victory, however, was that almost all government drug trials, from then on, focused on AZT - while over 100 other promising drugs were left uninvestigated.  Burroughs Wellcome stock went through the roof when the announcement was made. At a price of $8,000 per patient per year (not including blood work and transfusions), AZT is the most expensive drug ever marketed. Burroughs Wellcome's gross profits for next year are estimated at $230 million. Stock market analysts predict that Burroughs Wellcome may be selling as much as $2 billion worth of AZT, under the brand name Retrovir, each year by the mid-1990s - matching Burroughs Wellcome's total sales for all its products last year.  AZT is the only antiretroviral drug that has received FDA approval for treatment of AIDS since the epidemic began 10 years ago, and the decision to approve it was based on a single study that has long been declared invalid.  The study was intended to be a "double-blind placebo-controlled study," the only kind of study that can effectively prove whether or not a drug works. In such a study, neither patient nor doctor is supposed to know if the patient is getting the drug or a placebo. In the case of AZT, the study became unblinded on all sides, after just a few weeks.  Both sides of the contributed to the unblinding. It became obvious to doctors who was getting what because AZT causes such severe side effects that AIDS per se does not. Furthermore, a routine blood count known as CMV, which clearly shows who is on the drug and who is not, wasn't whited out in the reports. Both of these facts were accepted and confirmed by both the FDA and Burroughs Wellcome, who conducted the study.  Many of the patients who were in the trial admitted that they had analyzed their capsules to find out whether they were getting the drug. If they weren't, some bought the drug on the underground market. Also, the pills were supposed to be indistinguishable by taste, but they were not. Although this was corrected early on, the damage was already done. There were also reports that patients were pooling pills out solidarity to each other. The study was so severely flawed that its conclusions must be considered, by the most basic scientific standards, unproven.  The most serious problem with the original study, however, is that it was never completed. Seventeen weeks in the study, when more patients had died in the placebo group, the study was stopped short, and all subjects were put on AZT, no scientific study can ever be conducted to prove unequivocally whether AZT does prolong life.  Dr. Brook, who voted against approval, warned at the time that AZT, being the only drug available for doctors to prescribe to AIDS patients, would probably have a runaway effect. Approving it prematurely, he said, would be like "letting the genie out of the bottle."  Brook pointed out that since the drug is a form of chemotherapy, it should only be prescribed by doctors who have experience with chemotherapeutic drugs. Because of the most severe toxic effects of AZT - cell depletion of the bone marrow - patients would need frequent blood transfusions. As it happened, AZT was rampantly prescribed as soon as it was released, way beyond its purported parameters. The worst-case scenario had come true: Doctors interviewed by the New York Times later in 1987 revealed that they were already giving AZT to healthy people who had tested positive for antibodies to HIV.  The FDA's function is to weigh a drug's efficacy against its potential hazards. The equation is simple and obvious: A drug must unquestionably repair more than it damages, otherwise the drug itself may cause more harm than the disease it is supposed to fight. Exactly what many doctors and scientists fear is happening with AZT.  AZT was singled out among hundreds of compounds when Dr. Sam Broder, the head of the National Cancer Institutes (NCI), found that it "inhibited HIV viral replication in vitro." AIDS is considered a condition of immune suppression caused by the HIV virus replicating and eating its way into T-4 cells, which are essential to the immune system. HIV is a retrovirus which contains an enzyme called reverse transcriptase that converts viral RNA to DNA. AZT was thought to work by interrupting this DNA synthesis, thus stopping further replication of the virus.  While it was always known that the drug was exceedingly toxic, the first study concluded that 'the risk/benefits ratio was in favour of the patient."  In the study that won FDA approval for AZT, the one fact that swayed the panel of judges was that the AZT group outlived the placebo group by what appeared to be a landslide. The ace card of the study, the one that cancelled out the issue of the drug's enormous toxicity, was that 19 persons had died in the placebo group and only one in the AZT group. The AZT recipients were also showing a lower incidence of opportunistic infections.  While the data staggered the panel that approved the drug, other scientists insisted that it meant nothing - because it was so shabbily gathered, and because of the unblinding. Shortly after the study was stopped, the death rate accelerated in the AZT group. "There was no great difference after a while," says Dr. Brook, "between the treated and the untreated group."  "That study was so sloppily done that it really didn't mean much," says Dr. Joseph Sonnabend, a leading New York City AIDS doctor.  Dr. Harvey Bialy, scientific editor of the journal Biotechnology, is stunned by the low quality of science surrounding AIDS research. When asked if he had seen any evidence of the claims made for AZT, that it "prolongs life" in AIDS patients, Bialy said, "No. I have not seen a published study that is rigorously done, analyzed and objectively reported."  Bialy, who is also a molecular biologist, is horrified by the widespread use of AZT, not just because it is toxic, but because, he insists, the claims its widespread use are based upon are false. "I can't see how this drug could be doing anything other than making people very sick," he says.  The scientific facts about AZT and AIDS are indeed astonishing. Most ironically, the drug has been found to accelerate the very process it was said to prevent: the loss of T-4 cells.  "Undeniably, AZT kills T-4 cells [white blood cells vital to the immune system]" says Bialy. "No one can argue with that. AZT is a chain-terminating nucleotide, which means that it stops DNA replication. It seeks out any cell that is engaged in DNA replication and kills it. The place where most of this replication is taking place is the bone marrow. That's why the most common and severe side effect of the drug is bone marrow toxicity. That is why they [patients] need blood transfusions."  AZT has been aggressively and repeatedly marketed as a drug that prolongs survival in AIDS patients because it stops the HIV virus from replicating and spreading to healthy cells. But, says Bialy: "There is no good evidence that HIV actively replicates in a person with AIDS, and if there's isn't much HIV replication in a person with AIDS, and if there isn't much HIV replication to stop, it's mostly killing healthy cells."  University of California at Berkeley scientist Dr. Peter Duesberg drew the same conclusion in a paper published in the Proceedings, the journal of the National Academy of Sciences. Duesberg, whose paper addressed his contention that HIV is not a sufficient cause for AIDS, wrote: "Even if HIV were to cause AIDS, it would hardly be legitimate target for AZT therapy, because in 70 to 100 percent of antibody positive persons, proviral DNA is not detectable... and its biosynthesis has never been observed."  As a chemotherapeutic drug, explained Duesberg, explained Duesberg, AZT "kills dividing blood cells and other cells," and is thus "directly immunosuppressive."  "The cell is almost a million-fold bigger target than the virus, so the cell will be much, much more sensitive," says Duesberg. "Only very few cells, about one in 10,000 are actively making the virus containing DNA, so you must kill incredibly large numbers of cells to inhibit the virus. This kind of treatment could only theoretically help if you have a massive infection, which is not the case with AIDS. Meanwhile, they're giving this drug that ends up killing millions of lymphocytes [white blood cells]. It's beyond me how that could possibly be beneficial."  "It doesn't really kill them," Burroughs Wellcome scientists Sandra Lehrman argues. "You don't necessarily have to destroy the cell, you can just change the function of it. Furthermore, while the early data said that the only very few cells were infected, new data says that there may be more cells infected. We have more sensitive detection techniques now."  "Changes their function? From what - functioning to not functioning? Another example of mediocre science," says Bialy. "The 'sensitive detection technique' to which Dr. Lehrman refers, PCR, is a notoriously unreliable one upon which to base quantitative conclusions."  When specific questions about the alleged mechanisms of AZT are asked, the answers are long, contradictory, and riddled with unknowns. Every scientific point raised about the drug is eventually answered with the blanket response, "The drug is not perfect, but it's all we have right now." About the depletion of T-4 cells and other white cells, Lehrman says, "We don't know why T-4 cells go up at first, and then go down. That is one of the drug mechanisms that we are trying to understand."  When promoters of AZT are pressed on key scientific points, whether at the NIH, FDA, Burroughs Wellcome or an AIDS organization, they often become angry. The idea that the drug is "doing something," even though this is invariably followed with irritable admissions that there are "mechanisms about the drug and disease we don't understand," is desperately clung to. It is as if, in the eye of the AIDS storm, the official, government-agency sanctioned position is immunized against critique. Skepticism and challenge, so essential to scientific endeavour, is not welcome in the AZT debate, where it is arguably needed more than anywhere else.  The toxic effects of AZT, particularly bone marrow suppression and anemia, are so severe that up to 50 percent of all AIDS and ARC patients cannot tolerate it and have to be taken off it. In the approval letter that Burroughs Wellcome sent to the FDA, all of 50 additional side effects of AZT, aside from the most common ones, were listed. These included: loss of mental acuity, muscle spasms, rectal bleeding and tremors.  Anemia one of AZT's common side effects, is the depletion of red blood cells, and according to Duesberg, "Red blood cells are the one thing you cannot do without. Without red cells, you cannot pick up oxygen."  Fred, a person with AIDS, was put on AZT and suffered such severe anemia from the drug he had to be taken off it. In an interview in the AIDS handbook Surviving and Thriving With AIDS, he described what anemia feels like to the editor Michael Callen: "I live in a studio and my bathroom is a mere five-step walk from my be. I would just lie there for two hours; I couldn't get up to take those five steps. When I was taken to the hospital, I had to have someone come over to dress me. It's that kind of severe fatigue... The quality of my life was pitiful... I've never felt so bad... I stopped the AZT and the mental confusion, the headaches, the pains in the neck, the nausea, all disappeared within a 24-hour period."  "I feel very good at this point," Fred went on. "I feel like the quality of my life was a disaster two weeks ago. And it really was causing a great amount of fear in me, to the point where I was taking sleeping pills to calm down. I was so worried. I would totally lose track of what I was saying in the middle of a sentence. I would lose my directions on the street."  "Many AIDS patients are anemic even before they receive the drug." Says Burroughs Wellcome's Dr. Lehrman, "because HIV itself can infect the bone marrow and cause anemia."  This argument betrays a bizarre reasoning. If AIDS patients are already burdened with the problems such as immune suppression, bone marrow toxicity and anemia, is compounding these problems an improvement?  "Yes AZT is a form of chemotherapy." Says the man who invented the compound a quarter-century ago, Jerome Horowitz. "It is cytotoxic, and as such, it causes bone marrow toxicity and anemia. There are problems with the drug. It's not perfect. But I don't think anybody would agree that AZT is of no use. People can holler from now until doomsday that it is toxic, but you have to go with the results."  The results, finally and ironically, are what damns AZT. Several studies on the clinical effects of AZT - including the one that Burroughs Wellcome's approval was based on - have drawn the same conclusion: that AZT is effective for a few months, but that its effect drops of sharply after that. Even the original AZT study showed that T-4 cells went up for a while and then plummeted. HIV levels went down, and then came back up. This fact was well-known when the advisory panel voted for approval. As panel member Dr. Stanley Lemon said in the meeting, "I am left with the nagging thought after seeing several of these slides, that after 16 to 24 weeks - 12 to 16 weeks, I guess - the effect seems to be declining."  A follow-up meeting, two years after the original Burroughs Wellcome study, was scheduled to discuss the long range effects of AZT, and the survival statistics. As one doctor present at that meeting in May 1988 recall, "They hadn't followed up the study. Anything that looked beneficial was gone within half a year. All they had were some survival statistics averaging 44 weeks. The p24 didn't pan out and there was no persistent improvement in the T-4 cells."  HIV levels in the blood are measured by an antigen called p24. Burroughs Wellcome made the claim that AZT lowered this level, that is, lowered the amount of HIV in the blood. At the first FDA meeting, Burroughs Wellcome emphasized how the drug had "lowered" the p24 levels; at the follow-up meeting, they didn't mention it.  As that meeting was winding down, Dr. Michael Lange, head of the AIDS program at St. Luke's-Roosevelt Hospital in New York, spoke up about this. "The claim of AZT is made on the fact that it is supposed to have an antiviral effect," he said to Burroughs Wellcome, "and on this we have seen no data at all... Since there is a report in the Lancet [a leading British medical journal] that after 20 weeks or so, in many patients p24 came back, do you have any data on that?"  They didn't.  "What counts is the bottom line," one of the scientists representing Burroughs Wellcome summed up, "the survival, the neurologic function, the absence of progression and the quality of life, all of which are better. Whether you call it better because of some antiviral effect, or some other antibacterial effect, they are still better."  Dr. Lange suggested that the drug may be effective the same way a simple anti-inflammatory, such as aspirin, is effective. An inexpensive, nontoxic drug called Indomecithin, he pointed out, might serve the same function, without the devastating side effects.  One leading AIDS researcher, who was part of the FDA approval process, says today: "Does AZT do anything? Yes, it does. But the evidence that it does something against HIV is really not there."  "There have always been drugs that we use without knowing exactly how they work," says Nobel Prize winner Walter Gilbert. "The really important thing to look at is the clinical effect. Is the drug helping or isn't it?"  "I'm living proof that AZT works," says one person with ARC on AZT. "I've been on it for two years now, and I'm certainly healthier than I was two years ago. It's not a cure-all, it's not a perfect drug, but it is effective. It's slowing down the progression of the disease."  "Sometimes I feel like swallowing Drano," says another. "I mean, sometimes I have problems swallowing. I just don't like the idea of taking something that foreign to my body. But every six hours, I've got to swallow it. Until something better comes along, this is what is available to me."  "I am absolutely convinced that people enjoy a better quality of life and survive longer who do not take AZT," says Gene Fedorko, President of Health Education AIDS Liaison (HEAL). "I think it's horrible the way people are bullied by their doctors to take the drug. We get people coming to us shaking and crying because their doctors said they'll die if they don't take AZT. That is an absolute lie." Fedorko has drawn his conclusion from years of listening to the stories of people struggling to survive AIDS at HEAL's weekly support group.  "I wouldn't take AZT if you paid me," says Michael Callen, cofounder of New York City's PWA coalition, Community Research Initiative, and editor of several AIDS journals. Callen has survived AIDS for over seven years without the help of AZT. "I've gotten the shit kicked out me for saying this, but I think using AZT is like aiming a thermonuclear warhead at a mosquito. The overwhelming majority of long-term survivors I've known have chosen not to take AZT."  The last surviving patient from the original AZT trial, according to Burroughs Wellcome, died recently. When he died, he had been on AZT for three and one-half years. He was the longest surviving AZT recipient. The longest surviving AIDS patient overall, not on AZT, has lived for eight and one-half years.  An informal study of long-term survivors of AIDS followed 24 long-term survivors, all of whom had survived AIDS more than six years. Only one of them had recently begun taking AZT.  In the early days, AZT was said to extend lives. In actual fact, there is simply no solid evidence that AZT prolongs life.  "I think AZT does prolong life in most people," says Dr. Bruce Montgomery of the State University of New York City at Stony Brook, who is completing a study on AZT. "There are not very many long-tern survivors, and we really don't know why they survive. It could be luck. But most people are not so lucky."  "AZT does seem to help many patients," says Dr. Bernard Bahari, a New York City AIDS physician and researcher, "but it's very hard to determine whether it actually prolongs life."  "Many of the patients I see choose not to take AZT," says Dr. Don Abrams of San Francisco General Hospital. "I've been impressed that survival and lifespan are increasing for all people with AIDS. I think it has a lot to do with aerosolized Pentamidine [a drug that treats pneumocystis carinii pneumonia]. There's also the so-called plague effect, the fact that people get stronger and stronger when a disease hits a population. The patients I see today are not as fragile as the early patients were."  "Whether you live or die with AIDS is a function of how well your doctor treats you, not of AZT," says Dr. Joseph Sonnabend, one of New York's City's first and most reputable AIDS doctor, whose patients include many long-term survivors, although he has never prescribed AZT. Sonnabend was one of the first to make the simple observation that AIDS patients should be treated for their diseases, not just for their HIV infection.  Several studies have concluded that AZT has no effect on the two most common opportunistic AIDS infections, Pneumocystic Carinii Pneumonia (PCP) and Kaposi's Sarcoma (KS). The overwhelming majority of AIDS patients die of PCP, for which there has been an effective treatment for decades. This year, the FDA finally approved aerosolized Pentamidine for AIDS. A recent Memorial Sloan Kettering study concluded the following: By 15 months, 80% of people on AZT not receiving Pentamidine had a recurring episode. "All those deaths in the AZT study were treatable," Sonnabend says. "They weren't deaths from AIDS, they were deaths from treatable conditions. They didn't even do autopsies for that study. What kind of faith can one have in these people?"  "If there's any resistance to AZT in the general public at all, it's within the gay community of New York," says the doctor close to the FDA approval, who asked to remain anonymous. "The rest of the country has been brainwashed into thinking this drug really does that much. The data has all been manipulated by people who have a lot vested in AZT."  "If AIDS were not the popular disease that it is - the money-making and career-making machine - these people could not get away with that kind of shoddy science," says Bialy. "In all of my years in science I have never seen anything this atrocious." When asked if he thought it was at all possible that people have been killed as a result of AZT poisoning rather then AIDS he answered: "It's more than possible."  August 17, 1989: The government has announced that 1.4 million healthy, HIV antibody-positive Americans could "benefit" from taking AZT, even though they show no symptoms of disease. New studies have "proven" that AZT is effective in stopping the progression of AIDS in asymptomatic and early ARC cases. Dr. Fauci, the head of NIH, proudly announced that a trial that has been going on for "two years" had "clearly shown" that early intervention will keep AIDS at bay. Anyone who has antibodies to HIV and less than 500 T-4 cells should start taking AZT at once, he said. That is approximately 650,000 people. 1.4 million Americans are assumed HIV antibody-positive, and eventually all of them may need to take AZT so they don't get sick, Fauci contended.  The leading newspapers didn't seem to think it unusual that there was no existing copy of the study, but rather a breezy two-pages press release from the NIH. When SPIN called the NIH asking for a copy of the study, we were told that it was "still being written." We asked a few questions about the numbers. According to the press release, 3,200 early AARC and asymptomatic patients were devided into two groups, one AZT and one placebo, and followed for two years. The two groups were distinguished by T-4 cell counts; one group had less than 500, the other more than 500. These two were then divided into three groups each: high-dose AZT, low-dose AZT, and placebo. In the group with more than 500 T-4 cells, AZT had no effect. In the other group, it was concluded that low-dose AZT was the most effective, followed by high-dose. All in all, 36 out of 900 developed AIDS in the two AZT groups combined, and 38 out of 450 in the placebo group. "HIV-positive patients are twice as likely to get AIDS if they don't take AZT," the press declared.  However, the figures are vastly misleading. When we asked how many patients were actually enrolled for a full two years, the NIH said they did not know, but that the average time of participation was one year, not two.  "It's terribly dishonest the way they portrayed those numbers," says Dr. Sonnabend. "If there were 60 people in the trial those numbers would mean something, but if you calculate what the percentage is out of 3,200, the difference becomes minute between the two groups. It's nothing. It's hit or miss, and they make it look like it's terribly significant."  The study boasted that AZT is much more effective and less toxic at one-third the dosage than has been used for three years. That's the good news. The bad news is that thousands have already been walloped with 1,500 milligrams of AZT and possibly even died of toxic poisoning - and now we're hearing that one third of the dose would have done?  With all that remains so uncertain about the effects of AZT, it seems criminal to advocate expanding its usage to healthy people, particularly since only a minuscule percentage of the HIV-infected population have actually developed ARC or AIDS.  Burroughs Wellcome has already launched testing of AZT in asymptomatic hospital workers, pregnant women, and in children, who are getting liquid AZT. The liquid is left over from an aborted trial, and given to the children because they can mix it with water - children don't like to swallow pills. It has also been proposed that AZT be given to people who do not yet even test positive for HIV antibodies, but are "at risk."  "I'm convinced that if you gave AZT to a perfectly healthy athlete," says Fedorko, "he would be dead in five years."  In December 1988, the Lancet published a study that Burroughs Wellcome and the NIH do not include in their press kits. It was more expansive than the original AZT study and followed patients longer. It was not conducted in the United States, but in France, at the Claude Bernard Hospital in Paris, and concluded the same thing about AZT that Burroughs Wellcome's study did, except Burroughs Wellcome called their results "overwhelmingly positive," and the French doctors called theirs "disappointing." The French study found, once again, that AZT was too toxic for most to tolerate, had no lasting effect on HIV blood levels, and left the patients with fewer T-4 cells than they started with. Although they noticed a clinical improvement at first, they concluded that "by six months, these values had returned to their pretreatment levels and several opportunistic infections, malignancies and deaths occurred."  "Thus the benefits of AZT are limited to a few months for ARC and AIDS patients," the Fench team concluded. After a few months, the study found, AZT was completely ineffective.  The news that AZT will soon be prescribed to asymptomatic people has left many leading AIDS doctors dumbfounded and furious. Every doctor and scientist I asked felt that it was highly unprofessional and reckless to announce a study with no data to look at, making recommendations with such drastic public health implications. "This simply does not happen," says Bialy. "The government is reporting scientific facts before they've been reviewed? It's unheard of."  "It's beyond belief," says Dr. Sonnabend in a voice tinged with desperation. "I don't know what to do. I have to go in and face an office full of patients asking for AZT. I'm terrified. I don't know what to do as a responsible physician. The first study was ridiculous. Margaret Fishl, who has done both of these studies, obviously doesn't know the first thing about clinical trials. I don't trust her. Or the others. They're simply not good enough. We're being held hostage by second-rate scientists. We let them get away with the first disaster; now they're doing it again."  "It's a momentous decision to say to people, 'if you're HIV-positive and your T4-cells are below 500 start taking AZT,'" says the doctor who wished to remain anonymous. "I know dozens of people that I've seen personally every few months for several years now who have been in that state for more than five years, and have not progressed to any disease."  "I'm ashamed of my colleagues," Sonnabend laments. "I'm embarrassed. This is such shoddy science it's hard to believe nobody is protesting. Damned cowards. The name of the game is protect your grants, don't open your mouth. It's all about money... it's grounds for just following the party line and not being critical, when there are obviously financial and political forces that are driving this."  When Duesberg heard the latest announcement, he was particularly stunned over the reaction of Gay Men's Health Crisis President Richard Dunne, who said that GMHC now urged "everybody to get tested," and of course those who test positive to go on AZT. "These people are running into the gas chambers," says Duesberg. "Himmler would have been so happy if only the Jews were this cooperative." 

A new interview with Dr. Abraham "Avi" Loeb from Harvard and update on the subject of Oumuamua. We detailed point for point his findings that Oumuamua is an extremely strange object, regardless of its origins, and that it may be consistent with a light sail of some type. This is part one of a two part interview with Dr. Loeb. Have Aliens Found Us? A Harvard Astronomer on the Mysterious Interstellar Object ‘Oumuamua : https://www.newyorker.com/news/the-new-yorker-interview/have-aliens-found-us-a-harvard-astronomer-on-the-mysterious-interstellar-object-oumuamua "‘Oumuamua's Geometry Could be More Extreme than Previously Inferred", Siraj and Loeb, 2019. https://www.cfa.harvard.edu/~loeb/SL.pdf 6 Strange Facts about the Interstellar Visitor Oumuamua: https://blogs.scientificamerican.com/observations/6-strange-facts-about-the-interstellar-visitor-oumuamua/ "COULD SOLAR RADIATION PRESSURE EXPLAIN ‘OUMUAMUA'S PECULIAR ACCELERATION?", Bialy and Loeb, 2018 https://arxiv.org/pdf/1810.11490.pdf Is Oumuamua A Light Saul? Featuring Dr. Avi Loeb: https://youtu.be/VlpVIyBCG3s Why The Universe May Be Full Of Alien Civilizations Featuring Dr. Avi Loeb: https://youtu.be/6ckgBxRASTo Website: https://www.eventhorizonshow.com/ You can now support us on Patreon! https://www.patreon.com/EventHorizonShow Follow us on Twitter! https://twitter.com/jmgeventhorizon Follow us on Instagram! https://www.instagram.com/jmgeventhorizon/ MUSIC (Track names on screen in credits) Chris Zabriskie: https://chriszabriskie.bandcamp.com/ Kai Engel: https://kaiengel.bandcamp.com/ Stellardrone: https://stellardrone.bandcamp.com/ Miguel Johnson: https://migueljohnson.bandcamp.com

A new interview with Dr. Abraham "Avi" Loeb from Harvard and update on the subject of Oumuamua, the Fermi Paradox, interstellar objects. Life around red dwarf stars, solar flares, and the search for intelligent alien civilizations. This is part two of a two part interview with Dr. Loeb. Have Aliens Found Us? A Harvard Astronomer on the Mysterious Interstellar Object ‘Oumuamua : https://www.newyorker.com/news/the-new-yorker-interview/have-aliens-found-us-a-harvard-astronomer-on-the-mysterious-interstellar-object-oumuamua 6 Strange Facts about the Interstellar Visitor Oumuamua: https://www.cfa.harvard.edu/~loeb/SL.pdf "COULD SOLAR RADIATION PRESSURE EXPLAIN ‘OUMUAMUA'S PECULIAR ACCELERATION?", Bialy and Loeb, 2018 https://arxiv.org/pdf/1810.11490.pdf Is Oumuamua A Light Saul? Featuring Dr. Avi Loeb: https://youtu.be/VlpVIyBCG3s Why The Universe May Be Full Of Alien Civilizations Featuring Dr. Avi Loeb: https://youtu.be/6ckgBxRASTo Website: https://www.eventhorizonshow.com/ You can now support us on Patreon! https://www.patreon.com/EventHorizonShow Follow us on Twitter! https://twitter.com/jmgeventhorizon Follow us on Instagram! https://www.instagram.com/jmgeventhorizon/

How does your marketing strategy compare to the competition? Is your approach more tactical than strategic? In this episode of The Staffing Show podcast, Brad Bialy of [Haley Marketing](https://www.haleymarketing.com/) shares insights into rock star marketing and what the staffing industry can learn from professional sports, entertainment, and the largest online marketplaces.

Hart Halper aka New York Romantic is an artist primarily known for his chalk graffiti hearts, over 100,000 in downtown NYC. Hash started drawing hearts dotting the i in the “ Bialy” on his morning delivery bags at a Lower East Side bakery. He noticed that it gave him an uplifting feeling, so he shared the powerful symbol with downtown. Halper has drawn tens of thousands of chalk hearts on New York sidewalks because he feels New York is losing its romance, with people looking at phones instead of looking at each other. The artist hopes that chalking hearts (and words like “unity,” “peace” and ”love”) around the city might positively influence New Yorkers’ behavior and decisions. “Blueberry Herring” is Halper’s first solo exhibition. It is a romantic landscape with interactive chalk landscapes and paintings. The exhibition is open at the gallery Art of Our Century (137 w14th #3) until the 28th of February. https://artofourcentury.com/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

W tym odcinku rozgadujemy się na temat "filmów wojennych". Chwalimy, krytykujemy, gardzimy, szydzimy, polecamy i odradzamy. Trochę też spojlerujemy więc w opisie macie listę filmów wraz z timestampami - jeżeli planujecie zobaczyć dany film i nie chcecie sobie psuć zabawy możecie opuścić dany fragment podcastu. Poza tym ogłaszamy zwycięzcę konkursu na scenariusz i omawiamy FAQ/Erratę, która wyszła już jakiś czas temu ale nie mieliśmy jeszcze okazji jej komentować. Uwaga, W tym odcinku "recenzja" ostatniego z filmów jest dosyć emocjonalna i przesiąknięta naszym specyficznym poczuciem humoru. Pojawiają się też pojedyncze, mimowolne wulgaryzmy ale nie jest to nic, czego nie moglibyście usłyszeć czasem przy Boltowym stole od rozemocjonowanych graczy... Tak czy inaczej zostaliście ostrzeżeni :) Jesteśmy bardzo ciekawy waszej reakcji na ten odcinek więc z niecierpliwością czekamy na wasze komentarze. 0:00 Startujemy 14:16 Postepy w hobby 27:28 Nowości wydawnicz + FAQ 1:06:36 Szeregowiec Ryan 1:19:00 Kompania Braci 1:30:00 Furia 1:39:20 Bękarty Wojny 1:42:10 The Liberator 1:56:50 Dunkierka 2:00:16 Wróg u bram 2:10:36 Stalingrad(2013) 2:14:03 Bialy tygrys 2:19:00 Dead snow 2:20:39 Patton 2:23:13 Sahara 2:26:12 Big red one 2:28:24 Jak rozpętałem II Wojnę Światową 2:29:51 Pacyfik 2:37:50 Cienka czerwona linia 2:41:55 Listy z Iwo Jimy + Sztandar chwały 2:49:44 Pearl harbour 2:54:25 Szyfry Wojny 2:57:09 1941 2:58:46 Droga do zapomnienia 3:00:32 Przełącz ocalnoych 3:03:50 "Film, którego tytuł wstyd tu wpisać" Jak zawsze zapraszamy na nasz profil na Facebook'u, ➡️http://bit.ly/LZDnaFB Najlepsze t-shirty dla fanów Bolt Action (w sam raz pod frontową choinkę): ➡️https://totemsofwar.koszulkomat.eu Gdzie nas słychać?

This week we preview the plot to the "Con Air" sequel entitled "Con Water," Rush is a guest on the world's least popular gameshow, and we get a return visit from the Tradition Troll.  All that and more on  "Cruises, Cons, Trolls ."  And don't forget that you too can send us your "Situations" and photos of those sweet bialys at heresthesituationpodcast@gmail.comHosts: TJ Jagodowski and Rush HowellProducer: Nate DuFortComposer: Julie NicholsArt: Emily Kardamis Twitter: @TJandRushInstagram: @heresthesituation

I read from bialy to bibelot.   The word of the episode is "bias".   dictionarypod@gmail.com Facebook Twitter Instagram Patreon 917-727-5757

In this audio reenactment of the hilarious scene from the original film of "The Producers", by Mel Brooks, Max Bialystock, a down-and-out theatrical producer, meets Leo Bloom, a young accountant, sent to do his books. Just a few moments before this scene begins, Leo had walked into Bialy's office, and witnessed the older man in a somewhat compromising position with a much older lady. In the course of this later encounter, Bialy and Leo spar verbally over business and ethics, and whether the two have ever met. Featuring Pete Lutz as Bialystock and Jordan Bruster as Bloom, recorded (over Skype) specially for the entertainment of COVID-19 shut-ins. Enjoy!   We do not own the rights to this work, and infringement is not intended.

Are you ready to make 2020 your best year ever?  Brad Bialy joins me to review all the areas of your business that you need to make sure are up to speed.  We'll discuss; Does your website say 2020 or 2006? (Find out about ADA compliance here) Is your job board optimized to bring in more applications? Does ever social media post have a purpose? Are you telling a story with your content marketing? You can also download Haley Marketing's "Smart Marketing Checklist" at https://www.haleymarketing.com/smartmarketing/.

This week we are talking to Rachel Gross, who, along with her sister, Sarah, is the new owner of Bialy's Bagels in University Heights. She tells us about her path to bagels, which funny enough, involved starting a cream cheese business. We sat down with Rachel Gross at Bnai Jeshurun Congregation in Pepper Pike.

Title: How to enter the Kingdom of God Speaker: Steve Bialy Passage: John 3:1-21 Series: Life Recording Date: 22.09.2019 AM

In this episode, we sit down with Mickey and Liz Natale. Mickey and Liz are father-daughter partners of the barber shop called King Kuts in Skokie. Mickey started the business with his brother Kenny in 1962. Mickey has been working with Liz for many years. Kings Kuts epitomizes the neighborhood, family-owned barber shop. Some would say it’s a community center, or the Cheers of Skokie, where everybody knows your name. Personally, I had my first haircut at Kings Kuts, along with my son, my brother, and my father and grandfather also go to Kings Kuts. It’s a core part of my life. And it’s a core part of the community’s life. The episode walks us through the history of Kings Kuts, how it started and how it has evolved. The Village of Skokie marked the importance of Kings Kuts by creating an ordinance for Kings Kuts Day on October 6, 2012 in honor of their 50th year in business (https://www.egovlink.com/public_documents300/skokie/published_documents/Manager%20Department/BoardAgenda/2012-10-01/2012-10-01.pdf). Liz talks about how they started thek, “take your daughter to work day,” very early. By 13 she was the shampoo girl, and by 16 and a half, the first day you could enter barber school, she entered. By the way, their uncle owned the barber school. She has been working at Kings Kuts now for 36 years. They love working with each other. Mickey says, “if you can’t get along with Liz, there’s something wrong with you.” We talked about the ups of the business. The 70s were a tough time for Kings Kuts. From getting poor quality new barbers, to people keeping their hair long, they had to find ways to make ends meet. Mickey is a car guy, and he and his brother would repair people’s cars at night. Mickey used to race cars, but he sold his race car and bought equipment to fix cars in his garage. We also talk about the competition in the business between the high-end shops and the chains. The conversation turned towards their connections to their customers who have become like family, and their neighbors in the shopping center. We walked about the close relationship with Joel Jacobs who owned Kosher Gourmet before he passed away on new years eve of 2010. We also talked about the owners of New York Bagel and Bialy like going to Oli’s son’s wedding last year. They even talk about people coming in to Kings Kuts for nostalgic visits. People come into their shop and Poochies, and other local longtime businesses. Mickey is also famous for his red 1963 Chevrolet Corvette. People knew when it was Spring in Skokie when they’d see Mickey’s red Corvette sitting outside the shop. He bought it in 1966 and finally sold it in 2018. We then talk about my son Joey, and his sense of humor. Mickey tells the story of how he told a fellow customer he was 94 years old and goes to Northwestern University. He was 6. We talk about the pets in the store like their zebra finches. They started with 2 and now have 18 birds. They talk about how they take care of them. When Mickey does eventually retire, Liz plans to rent a chair from another barber shop in the area. Hopefully Kings Kuts will be open for many, many years before that happens. Kings Kuts is located at 3558 Dempster Street Skokie, IL 60076 and their phone number is 847-673-9663. Call them for an appointment or stop in! I’d like to thank several people for help with today’s show. This includes my real estate brokerage, Dreamtown Realty in Evanston for helping me with my graphics for the show. I’d like to thank Industrious in Evanston for use of their space to record follow them on Instagram at @industriousevanston. And if listening to this podcast gave you the bug to buy or sell real estate, give me call or go to my real estate website at http://www.aaronmasliansky.com And don’t forget to subscribe! Thank you.

Released: 10 February 2019 Duration: 16 Minutes, 51 Seconds   Abraham Loeb and Shmuel Bialy kicked up a kerfuffle when they wrote a paper suggesting that one possible explanation for ‘Oumuamua was that it could be an artificial object, in other words, an alien spacecraft—specifically, a lightsail. The two have been praised for their boldness and condemned for their recklessness, but little has been said concerning the possibility of detecting a lightsail as a technosignature in comparison to detecting a “conventional” technosignature such as the radio and laser beacons that SETI searches for. When we look out into the universe for signs of intelligence, if there are technosignatures to be seen, what technologies ought we to expect to be the most common?      Links Stagnant Supercivilizations and Interstellar Travel “Could Solar Radiation Pressure Explain ‘Oumuamua’s Peculiar Acceleration?” Bialy and Loeb  Predictably, online media go nuts over ‘Oumuamua and Harvard scientists; “Scientists are perfectly happy to publish an outlandish idea.” by Eric Berger Breakthrough Starshot  lightsail (Wikipedia) The Interstellar Age: The Story of the NASA Men and Women Who Flew the Forty-Year Voyager Mission by Jim Bell NASA Voyager 2 Could Be Nearing Interstellar Space The Great Filter—Are We Almost Past It? by Robin Hanson SETI as a Process of Elimination Credits Written and Presented by: Nick Nielsen Postproduction: Paul Carr Music: DJ Spooky   This podcast episode is released under the Creative Commons Attribution/Share-Alike license

El 19 de octubre de 2017 el asteroide Oumuamua paso muy cerca de nuestro planeta Tierra. Este asteroide es el primero localizado por NASA y ESA procedente de fuera de nuestro sistema solar. Un artículo elaborado por Bialy y Loeb y recientemente aceptado por The Astrophysical Journal Letters plantearon la hipótesis de un origen alienígena de este asteroide. En este programa abordamos este curioso caso. Participan: Sara Hernández, Edgar Luis Conduce: Nacho Hernández Las músicas con licencia Creative Commons utilizadas en está entrega son: - Strannik - Out of Mirror - Blue Wave Theory - Mermaid in Japan Nuestra vías de contacto son: Twitter: @CDNantucket email: cronicasnantucket@gmail.com Telegram: https://t.me/CronicasdeNantucket Facebook: https://www.facebook.com/CronicasDeNantucket/ Blog: https://cronicasdenantucket.blogspot.com Enlaces a los podcast y canales amigos: La Posada de Términa: https://us.ivoox.com/es/podcast-posada-termina_sq_f1314629_1.html El legado de Kripton: https://www.ivoox.com/podcast-podcast-el-legado-krypton_sq_f146987_1.html Terra Máxica: https://www.youtube.com/channel/UCghpXsKMuvaFaHxuDMudrXw La Madriguera de Rocket: https://www.youtube.com/channel/UCvtXE76VCIOmKAO8hAzL3ng El terror no tiene podcast: http://www.ivoox.com/p_sq_f1254614_1.html Terrorvision: https://www.ivoox.com/podcast-terrorvision_sq_f1261848_1.html Cronocine: https://us.ivoox.com/es/podcast-cronocine_sq_f1449964_1.html Applelianos: https://us.ivoox.com/es/podcast-podcast-applelianos_sq_f1170563_1.html La Guarida del Lobo: https://www.ivoox.com/podcast-guarida-del-lobo_sq_f1611488_1.html Búscanos en ivoox e itunes y dejanos tus comentarios. Apoya el proyecto de estos humildes balleneros dando like a los programas si te gustan: http://www.ivoox.com/podcast-cronicas-nantucket_sq_f1274025_1.html https://itunes.apple.com/us/podcast/cronicas-de-nantucket/id1102234297?mt=2 .

Orzel Bialy - Wiersz Adam Szeluga by Radio RAMPA

hilarious comedian and america's sweetheart Beth Stelling joins the boys to discuss the mastery of john wick, her former life as a barista, and the highest honor anyone can achieve: having a sandwich named after her. also, joel reveals fatherhood tips and karl goes on a tapas rant and advocates for lunch wine normalization.

A great conversation with Erin Kowalski from Bialy's Wellness Foundation! Sooo many people asked for her to be a guest and she was phenomenal. The story of Bialy is a tough one and I think it is soooo important for people to hear. "No kill" is such a buzzword, rightfully so, and unfortunately sometimes all avenues have been exhausted and tough decisions have to be made. That is reality. It does not mean it is easy. No one is more genuine and giving than Erin.  We also reminisce about Lt. Dan...it is a great listen. 

0000034E 0000034E 0000912E 0000912E 0024B7CB 0024B7CB 00008A61 00008A61 00128968 00128968

Your weekly news podcast served on a bagel. Coming to you this week from Kossar's Bagel and Bialy in the Lower East Side of Manhattan. We reviewed the bagel and to the owner, reviewed the movie the Big Short, and discussed the fine line between being crazy (Kanye) and a genius (Daniel Day Lewis) in our culture. Visit www.Schmearsthedeal.com for more info.

Ćwicz 5-15 minut dziennie, by rozwijać dystans wobec własnych myśli i emocji. Nie chodzi o to, by przestać oceniać, ale by nie przywiązywać się do swoich osądów. Myśl to tylko myśl, nie więcej, nie mniej. ps. pamiętajmy że celem medytacji nie jest poprawa nastroju, tylko nauczenie się bycie z tym co jest i nieocenianie tego :) oraz większa świadomość naszego umysłu i myśli- jako tylko myśli i emocji jako tylko emocji (oczywiście wymaga to ćwiczeń) choć częstym efektem ubocznym medytacji jest większy spokój to oczekiwanie takiego rezultatu raczej zmniejszy nasze szanse na to :(

What better way to kick off this edition of the Livecast than with an argument about bagel preferences. Yes, you can hear four Jews arguing about bagels. Also discussed are terrible movies starring Liam Neeson and whether Julianne Moore looks like Rocky Dennis from Mask. In the second hour, we discuss the Tim Lambesis trial and fan reactions as well as poor ole Joey Belladonna. Here is this week's playlist: Defaced Creation – Macabre Exposure Of Fleshly Devotion Ludicra – In Stable Sigh – In Devil's Arms Unleashed – Dead Forever Listen to the Metal Injection Livecast on Stitcher or on iTunes (please leave a rating/review as well). Also, make sure to follow us on Facebook, Twitter and Youtube. Join us live next week starting at 6pm Eastern (3PM Pacific Time, 11pm In London, 10am Mon in Sydney) and going until 8PM eastern time for an all new edition of the Livecast. 

Casting Director extraordinaire Sharon Bialy (Breaking Bad, The Walking Dead, Rudy...) joins us on The Matthew Aaron Show this Friday (11/16) evening starting at 6pm PT. Sharon sits down with Matt to discuss her career, how the process of casting a film or TV show works, what casting directors look for in actors and her new book How to Audition on Camera (A Hollywood Insider's Guide) which is available now for purchase and download on Kindle. Show starts at 6pm PT (8pm CT / 9pm ET). Listen live via our website or subscribe for free and download the show on iTunes. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

My guests today are, voice actor and cartoon dork , and local guy and VH1 talking head show dork, .  We bonded on film, the joy of diners and then… we talk about comedy. Again. And I enjoyed it.   Notes: – Bradley Whitford I said “percentage of the watchers” fantastic. English is my first Language. - where is she now? Tony Dimond’s FIRST great invention? I forgot to ask during the show and the real answer is, according to Tony is… Direct Deposit! – owned by the Indigo Girls   Tony recommends … a website that gathers information Mike recommends , and soon:    Thanks for listening. Take care of each other out there, Jackie   My website has a player, standup schedule and videos, the merch (CD/T-shirt opportunities), the donation button: or .The , , and a very basic free app for the are available.   Credits: Audio leveling by (part of a great production company in NY).The music is by . My Website is designed by : who has his OWN (road comic interviews… fascinating)

This is an interview on LIB Radio with Dr. Harvey Bialy, recorded June 14, 2006. Dr. Bialy discusses the difference between HIV/AIDS and STDs, why HIV is not sexually tramsitted as proven by the Padian study, and AIDS in Africa. Dr. Bialy has recently published a new book, Oncogenes, Aneuploidy, and AIDS: The Scientific Life and Times of Peter H. Duesberg, available at amazon.com.